Clinical Trials on High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements in New Zealand

Total 37 results

Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Withdrawn

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Burkitt Lymphoma | Refractory Burkitt... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Double-Expressor Lymphoma | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
National Cancer Institute (NCI)

Completed

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma

United States
Curis, Inc.

Completed

Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

United States, Spain
Memorial Sloan Kettering Cancer Center
Takeda

Recruiting

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

B-Cell Lymphoma | Large B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | Mediastinal Large B-cell Lymphoma | High-grade B Cell Lymphoma

United States
Roswell Park Cancer Institute

Not yet recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Hoffmann-La Roche

Completed

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

Diffuse Large B-cell Lymphoma | High-Grade B-cell Lymphoma

United States, Spain, Australia, Denmark
Peter MacCallum Cancer Centre, Australia
Hoffmann-La Roche

Active, not recruiting

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (COALITION)

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma

Australia
Curis, Inc.
The Leukemia and Lymphoma Society

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Lymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditions

United States
MEI Pharma, Inc.

Terminated

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone B Cell Lymphoma | High Grade Non-Hodgkin's Lymphoma

United States, Switzerland
Weill Medical College of Cornell University
M.D. Anderson Cancer Center; Massachusetts General Hospital; Genentech, Inc.

Completed

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R)

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma

United States
AstraZeneca

Recruiting

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin Lymphoma

Korea, Republic of, United States, Japan, Australia, Taiwan
Northwestern University
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Active, not recruiting

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Plasmablastic Lymphoma | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Adult Burkitt Lymphoma | MYC Gene Mutation

United States
Kite, A Gilead Company

Approved for marketing

Axicabtagene Ciloleucel Expanded Access Study (ZUMA-9)

Relapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Study of CAR-T Therapy in Older Patients

Lymphoma | Lymphoma, B-Cell | Multiple Myeloma | High-grade B-cell Lymphoma | Refractory B-Cell Lymphoma | DLBCL NOS

United States
Miltenyi Biomedicine GmbH

Recruiting

DALY II USA/ MB-CART2019.1 for DLBCL

Central Nervous System Lymphoma | Transformed Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL) | Relapsed Diffuse Large B Cell Lymphoma

United States
Kite, A Gilead Company

Completed

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)

Relapsed Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL)

United States, Netherlands, Canada, France, Germany, Israel
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL

Korea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada
New York Medical College

Completed

Treatment for Advanced B-Cell Lymphoma (REBOOT)

Diffuse Large Cell Lymphoma | Burkitt's Lymphoma | High Grade B-cell Lymphoma

United States
Schrödinger, Inc.

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

Follicular Lymphoma | Splenic Marginal Zone Lymphoma | Burkitt Lymphoma | Plasmablastic Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Non Hodgkin Lymphoma | Primary Effusion Lymphoma | DLBCL | High-grade B-cell Lymphoma | Primary Mediastinal... and other conditions

United States, Moldova, Republic of
Biogen

Completed

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

United States, Canada
Monte Rosa Therapeutics, Inc

Recruiting

Study of Oral MRT-2359 in Selected Cancer Patients

NSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast Cancer

United States, Canada
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Withdrawn

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent... and other conditions

United States
Fred Hutchinson Cancer Center

Completed

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
Roswell Park Cancer Institute

Completed

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Primary Myelofibrosis | Polycythemia Vera | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

HIV Infection | Clear Cell Renal Cell Carcinoma | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Down Syndrome | Philadelphia Chromosome Positive | Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Childhood B Acute Lymphoblastic Leukemia | Adult B Lymphoblastic Lymphoma | Ann Arbor Stage I B Lymphoblastic Lymphoma | Ann Arbor Stage... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Switzerland, Ireland
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI); American Lebanese Syrian Associated Charities...

Recruiting

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Low Grade Glioma (LGG) of Brain With BRAF Aberration | High Grade Glioma (HGG) of the Brain With BRAF Aberration | Low Grade Glioma of Brain With Neurofibromatosis Type 1

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Burkitt Lymphoma | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
Dana-Farber Cancer Institute
The Leukemia and Lymphoma Society

Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Myelodysplastic-Myeloproliferative Diseases | Waldenstrom Macroglobulinemia | Smoldering Multiple Myeloma | Chronic Lymphocytic Leukemia (CLL) | Hematological Malignancies | Monoclonal Gammopathy of Undetermined Significance (MGUS) | B-cell Malignancy, Low-grade | Myelodysplastic Syndrome With Low-grade... and other conditions

United States
Roswell Park Cancer Institute

Active, not recruiting

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Acute Myeloid Leukemia | Polycythemia Vera | Myelofibrosis | Chronic Myelomonocytic Leukemia | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Sickle Cell Disease | Myelodysplastic Syndrome | Plasma Cell Myeloma | Chronic Granulomatous... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Down Syndrome | Myeloid Leukemia Associated With Down Syndrome | B Acute Lymphoblastic Leukemia Associated With Down Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Malignant Solid Neoplasm | Nasopharyngeal Carcinoma | Adenoid Cystic Carcinoma | Transitional Cell Carcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Chordoma | Gestational Trophoblastic Tumor | Pseudomyxoma Peritonei | Cervical Adenocarcinoma | Vaginal Adenocarcinoma | Vaginal Squamous Cell... and other conditions

United States, Guam

Clinical Trials on High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations